Education
About Us
Working with TipRanks
Follow Us
Gland Pharma Ltd. (IN:GLAND)
:GLAND
RESEARCH TOOLSreports
Total Valuation
Gland Pharma Ltd. has a market cap or net worth of ₹308.73B. The enterprise value is ₹298.88B.
Market Cap₹308.73B
Enterprise Value₹298.88B
Share Statistics
Gland Pharma Ltd. has 164,756,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding164,756,420
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Gland Pharma Ltd.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 11.55%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)11.55%
Return on Capital Employed (ROCE)0.18
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.50
Inventory Turnover1.36
Valuation Ratios
The current PE Ratio of Gland Pharma Ltd. is 36.64. Gland Pharma Ltd.’s PEG ratio is 1.61.
PE Ratio36.64
PS Ratio0.00
PB Ratio10.38
Price to Fair Value2.80
Price to FCF600.07
Price to Operating Cash Flow160.37
PEG Ratio1.61
Income Statement
In the last 12 months, Gland Pharma Ltd. had revenue of 56.17B and earned 6.99B in profits. Earnings per share was 42.40.
Revenue56.17B
Gross Profit33.27B
Operating Income17.33B
Pretax Income10.63B
Net Income6.99B
EBITDA12.69B
Earnings Per Share (EPS)42.40
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Gland Pharma Ltd. pays an annual dividend of ₹20, resulting in a dividend yield of 1.07%
Dividend Per Share₹20
Dividend Yield1.07%
Payout Ratio37.02%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.41
52-Week Price Change0.44%
50-Day Moving Average1.59K
200-Day Moving Average1.65K
Relative Strength Index (RSI)77.81
Average Volume (3m)6.85K
Important Dates
Gland Pharma Ltd. upcoming earnings date is Jul 16, 2025, TBA (Confirmed).
Last Earnings DateMay 20, 2025
Next Earnings DateJul 16, 2025
Ex-Dividend DateAug 14, 2025
Financial Position
Gland Pharma Ltd. as a current ratio of 4.33, with Debt / Equity ratio of 0.23%
Current Ratio4.33
Quick Ratio3.26
Debt to Market Cap0.01
Net Debt to EBITDA-1.77
Interest Coverage Ratio41.27
Taxes
In the past 12 months, Gland Pharma Ltd. has paid 3.64B in taxes.
Income Tax3.64B
Effective Tax Rate0.34
Enterprise Valuation
Gland Pharma Ltd. EV to EBITDA ratio is 18.40, with an EV/FCF ratio of 44.04.
EV to Sales4.16
EV to EBITDA18.40
EV to Free Cash Flow44.04
EV to Operating Cash Flow25.53
Balance Sheet
Gland Pharma Ltd. has ₹30.50B in cash and marketable securities with ₹3.14B in debt, giving a net cash position of -₹27.36B billion.
Cash & Marketable Securities₹30.50B
Total Debt₹3.14B
Net Cash-₹27.36B
Net Cash Per Share-₹166.07
Tangible Book Value Per Share₹533.96
Margins
Gross margin is 57.00%, with operating margin of 30.86%, and net profit margin of 12.44%.
Gross Margin57.00%
Operating Margin30.86%
Pretax Margin18.92%
Net Profit Margin12.44%
EBITDA Margin22.59%
EBIT Margin15.86%
Analyst Forecast
The average price target for Gland Pharma Ltd. is ₹1,435.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target₹1,435.00
Price Target Upside-4.08% Downside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―